Development and testing of new vaccines against EBV and other viruses

[rvallee]

Mid-way 2025 for completion.

 

[forestglip]

Vaccine against Epstein-Barr virus may enter clinical trial next year
German startup plans to test EBV-001 in preventing mononucleosis, MS risk factor

https://multiplesclerosisnewstoday....accine-ebv-001-may-enter-clinical-trial-2024/

Their newest press release has more focus on ME/CFS:

EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV). The aim is to protect people from a range of serious diseases such as infectious mononucleosis, secondary diseases such as multiple sclerosis and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and certain types of cancer.

Link

 

[Sly Saint]

Start-up EBViously announces its launch

EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV). The aim is to protect people from a range of serious diseases such as infectious mononucleosis, secondary diseases such as multiple sclerosis and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and certain types of cancer.

EBViously is based on a research project supported by Helmholtz Munich and the German Center for Infection Research (DZIF). The vaccine was developed by leading scientists in the field of Epstein-Barr virus research and the aim is now for the company to carry out professional product development.

Innovative vaccine based on virus-like particles
EBViously’s first vaccine candidate utilises virus-like particles (VLPs) that are structurally derived from EBV. These are similar to the Epstein-Barr virus, but do not contain viral genetic material and are therefore not infectious. With the authentic structure of the virus, these VLPs “feign” an infection to the immune system and thus trigger a targeted immune response against EBV. Preclinical studies and animal models have impressively confirmed these properties.

https://www.the-microbiologist.com/news/start-up-ebviously-announces-its-launch/4801.article